Soleno Therapeutics (SLNO) Accounts Payables (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Accounts Payables data on file, last reported at $12.4 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 125.9% year-over-year to $12.4 million in Q1 2026; TTM through Mar 2026 was $12.4 million, a 125.9% increase from a year earlier, with the FY2025 full-year figure at $12.4 million, up 40.0% from the prior year.
• Accounts Payables for Q1 2026 stood at $12.4 million, roughly flat from $12.4 million in the prior quarter.
• Over the last five years, Accounts Payables for SLNO reached as high as $12.4 million in Q4 2025 and fell as low as $1.8 million in Q4 2022.
• Historically, Accounts Payables has averaged $5.5 million across 5 years, with a median of $3.7 million in 2024.
• Across the five-year window, Accounts Payables slumped 48.36% in 2022 and jumped 188.77% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $1.8 million in 2022, then soared by 77.21% to $3.1 million in 2023, then jumped by 182.06% to $8.9 million in 2024, then soared by 40.0% to $12.4 million in 2025, then fell by 0.39% to $12.4 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $12.4 million in Q1 2026, $12.4 million in Q4 2025, and $8.1 million in Q3 2025.